Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: A Swiss perspective

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 499-523

  Wasserfallen, Jean Blaise ^a   Krieg, Marc Antoine ^a   Greiner, Roger Axel ^b   Lamy, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

Cost utility analysis; Hip fracture; Modelling studies; Osteoporosis; Risedronate; Switzerland; Vertebral fracture

Indexed keywords

RISEDRONIC ACID;

AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PROBABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; SWITZERLAND; TREATMENT DURATION; VERTEBRA FRACTURE; WOMEN'S HEALTH; WRIST FRACTURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; MARKOV CHAINS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPINAL FRACTURES; SWITZERLAND;

EID: 55049098975     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802332770     Document Type: Article

References (46)

1. NIH Consensus Development Panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association 2001; 285: 785-795.
2. Tosteson AN, Gabriel SE, Grove MR et al. Impact of Hip and Vertebral Fractures on Quality-Adjusted Life Years. Osteoporosis International 2001; 12: 1042-1049.
3. Johnell O, Kanis JA, Odén A et al. Mortality after osteoporotic fractures. Osteoporosis International 2004; 15: 38-42.
4. Kanis J, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis International 2005; 16: 229-238.
5. Lippuner K, von Overbeck J, Perrelet R et al. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporosis International 1997; 7: 414-425.
6. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporosis International 2005; 16(Suppl. 2): S8-S17.
7. Schwenkglenks M, Lippuner K, Hauselmann HJ et al. A model of osteoporosis impact in Switzerland 2000-2020. Osteoporosis International 2005; 16: 659-671.
8. Boonen S, Laan RF, Barton IP et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International 2005; 16: 1291-1298.
9. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Journal of the American Medical Association 1999; 282: 1344-1352.
10. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine 2001; 344: 333-340.
11. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International 2000; 11: 83-91.
12. Stevenson M, Llyod Jones M, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technology Assessment 2005; 9: 1-160.
13. Kanis JA, Borgström F, Johnell O et al. Cost effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporosis International 2004; 15: 862-871.
14. Borgström F, Carlsson A, Sintonen H et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporosis International 2006; 17: 996-1007.
15. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis International 2001; 12: 989-995.
16. Tosteson AN, Jonsson B, Grima DT et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis International 2001; 12: 501-505.
17. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. Journal of Clinical & Endocrinology Metabolism 2000; 85: 3109-3115.
18. Stock JL, Bell NH, Chesnut CH 3rd et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. American Journal of Medicine 1997; 103: 291-297.
19. Watts N, Barton I, Olszynski W et al. Sustained reduction of vertebral fracture risk in the year after discontinuation of risedronate treatment. Osteoporosis International 2005; 16: [Abstract s40].
20. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-75.
21. Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. Journal of the American Medical Association 1990; 263: 665-668.
22. Binkley N, Kiebzak GM, Lewiecki EM et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. Journal of Bone and Mineral Research 2005; 20: 195-201.
23. Swiss Federal Statistical Office SFSO 2000. Available at: http://www.bfs.admin.ch/bfs/portal/en/index/dienstleistungen/ publikationen_statistik/publikationskatalog.html (accessed 6th May 2008).
24. Melton LJ 3rd, Thamer M, Ray NF et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997; 12: 16-23.
25. Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32: 120-126.
26. Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. American Journal of Medicine 2003; 115: 209-216.
27. Trombetti A, Herrmann F, Hoffmeyer P et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporosis International 2002; 13: 731-737.
28. Kanis JA, Oden A, Johnell O et al. The components of excess mortality after hip fracture. Bone 2003; 32: 468-473.
29. Morant J, Ruppanner H (eds). Compendium Suisse des Médicaments. Documed, Basel, 2005. Available at: http://www.kompendium.ch/Search.aspx (accessed 6th May 2008).
30. TARMED. Thrif médical Suisse. Available at: http://www.tarmedsuisse.ch/113.html?&L=1 (accessed 6th May 2008).
31. Lamy O, Simard N, Krieg MA et al. Osteoporosis is largely underdiagnosed and undertreated: The Lausanne survey of patients admitted for a potentially osteoporotic fracture. Osteoporosis International 2006; 17(Suppl. 1.): S62.
32. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporosis International 2007; 11: 1481-1491.
33. Schürch MA, Rizzoli R, Mermillod B et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. Journal of Bone and Mineral Research 1996; 12: 1935-1942.
34. Jonsson B. Targeting high-risk populations. Osteoporosis International 1998; 8(Suppl. 1): S13-S16.
35. Cranney A, Tugwell P, Zytaruk N et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrinology Review 2002; 4: 524-528.
36. Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of fife of Colles' fracture patients. Osteoporosis International 1999; 9: 196-199.
37. Johnell O, Jonsson B, Jonsson L et al. Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21: 305-314.
38. Borgström F, Johnell O, Kanis JA et al.= At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis. Osteoporosis International 2006; 17: 1459-1471.
39. Cramer JA, Lynch NO, Gaudin AF et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clinical Therapy 2006; 28: 1686-1694.
40. Caro JJ, Ishak KJ, Huybrachts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis International 2004; 15: 1003-1008.
41. Schousboe JT, Nyman JA, Kane RL et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Annals of Internal Medicine 2005; 142: 734-741.
42. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause, Society. Menopause 2006; 13: 340-367.
43. Graafmans WC, Ooms ME, Bezemer PD et al. Different risk profiles for hip fractures and distal forearm fractures: a prospective study. Osteoporosis International 1996; 6: 427-431.
44. Cumming RG. Nursing Home Residence and Risk of Hip Fracture. American Journal of Epidemiology 1996; 143: 1191-1194.
45. Studies of Osteoporotic Fractures (SOR In: Actonel Global Health Economics Osteoporosis Model. User Manual. Innovus Research Inc., Burlington, Ontario, Canada, 1999.
46. Jönsson B, Hedbrant J, Johnell O. A computer simulation-model to analyse the cost-effectiveness of fracture prevention of osteoporosis. EFI Research Paper NR 6525, Stockholm School of Economics, Sweden, 1993.